<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025205</url>
  </required_header>
  <id_info>
    <org_study_id>630-0014</org_study_id>
    <nct_id>NCT02025205</nct_id>
  </id_info>
  <brief_title>Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>A Multicentre, Prospective, Randomized, Controlled, One-way Crossover Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonx International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonx Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized, controlled, one-way crossover study is to assess and
      compare the efficacy of the Zephyr endobronchial valves vs. Standard of Care (SoC) in
      patients suffering from COPD with Homogeneous Emphysema. Patients will be followed up for 12
      months after randomization. Patients in the SoC arm will crossover to the EBV treatment arm
      after the 6-month visit and will be followed up for 6 additional months.The primary objective
      is the variation of FEV1 between baseline and 3-month follow-up visit. The secondary
      objectives will evaluate quality of life, exercise capacity, dyspnea (including BODE index)
      changes, target lobe volume reduction, as well as safety outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Forced Expiratory Volume in 1 s (FEV1) (ITT Population)</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Percentage change in FEV1 at 3 months relative to Baseline in the EBV group, compared to the SoC group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Target Lobe Volume for EBV Group (ITT Population)</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Target Lobe Volume for EBV Group (ITT Population)</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects in the EBV Group With a Target Lobe Volume Reduction (TLVR) of ≥ 350ml at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>The threshold of TLVR ≥350 mL was used to determine the proportion of subjects that achieved this amount of TLVR in the EBV group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in FEV1 (L) Post Bronchodilator at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>The mean absolute change in FEV1(L) relative to Baseline at 3 months between the EBV and SoC groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in FEV1 (% Predicted) Post Bronchodilator at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>The mean absolute change in FEV1(% Predicted) relative to Baseline at 3 months between the EBV and SoC groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Residual Volume (RV) at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Residual Volume (RV) at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean percent change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Predicted Change in Residual Volume at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Percent predicted change in RV relative to Baseline at 3 months between the EBV and SoC groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Six-Minute Walk Distance at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Six-Minute Walk Distance at 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean percent change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the SGRQ Total Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the St. George's Respiratory Questionnaire Total Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change (%) in the SGRQ Total Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean percent change in the SGRQ Total Score from Baseline to 3 months in the EBV group compared to the SoC group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the mMRC Dyspnea Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the Modified Medical Research Council (mMRC) Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change (%) in the mMRC Dyspnea Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean percent change in the mMRC Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in the CAT Total Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the COPD Assessment Test (CAT) Total Score from Baseline to 3 months in the EBV group compared to the SoC group.
The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change (%) in CAT Total Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease. Higher scores denote a more severe impact of COPD on a patient's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in EQ-5D Summary Index From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.
EQ-5D is a standardized instrument to measure health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D health states may be converted into a single summary index by applying a formula that attaches weights to each of the levels in each dimension. The maximum score of 1 indicates the best health state, while 0 indicates the worst health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change (%) in EQ-5D Summary Index From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean percent change in EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in EQ-5D VAS (Health State Today) Score From Baseline to 3 Months</measure>
    <time_frame>At baseline and after 3 months</time_frame>
    <description>Mean absolute change in the EQ-5D VAS (Health State Today) Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>COPD Patients With Homogeneous Emphysema</condition>
  <condition>Endoscopic Lung Volume Reduction With Endobronchial Valve</condition>
  <arm_group>
    <arm_group_label>ELVR with Endobronchial Valves</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endobronchial Valve</intervention_name>
    <description>Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve</description>
    <arm_group_label>ELVR with Endobronchial Valves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homogeneous emphysema

          -  15% ≤ FEV1 ≤ 45% predicted

          -  TLC &gt; 100% predicted

          -  RV ≥ 200% predicted

          -  6MWT ≥ 150 m

          -  Non-smoker &gt; 8 weeks prior to study entry

          -  Absence of Collateral Ventilation in the target lobe

        Exclusion Criteria:

          -  Active pulmonary infection

          -  More than 3 exacerbations with hospitalizations over the past 12 months

          -  Pulmonary hypertension (sPAP &gt; 45 mmHg)

          -  MI or other relevant CV events in the past 6 months

          -  Alpha-1 antitrypsin deficiency

          -  Bronchiectasis

          -  Prior LVR or LVRS procedure

          -  &gt; 20% difference in perfusion between right and left lung

          -  Hypercapnia (paCO2 &gt; 55 mmHg

          -  Asthma

          -  Use of more than 25 mg/day prednisolone or equivalent

          -  Severe bullous emphysema

          -  Systemic or malignant disease with high death probability within 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arschang Valipour, MD, PhD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology Otto-Wagner-Spital 1140 Wien / Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Herth (co-principal investigator), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf Eberhardt (co-principal investigator), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig-Boltzmann-Institut für COPD und Pneumologische Epidemiologie</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Westdeutsches Lungenzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenabteilung Thoraxzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitäts klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of pulmonary dieases, University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <results_first_submitted>December 17, 2018</results_first_submitted>
  <results_first_submitted_qc>July 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2019</results_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BLVR With Zephyr Endobronchial Valves</title>
          <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ELVR With Endobronchial Valves</title>
          <description>Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
Endobronchial Valve: Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.3" spread="6.3"/>
                    <measurement group_id="B2" value="63.2" spread="6.0"/>
                    <measurement group_id="B3" value="63.7" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.7" spread="10.0"/>
                    <measurement group_id="B2" value="165.4" spread="9.1"/>
                    <measurement group_id="B3" value="166.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" spread="15.4"/>
                    <measurement group_id="B2" value="62.2" spread="12"/>
                    <measurement group_id="B3" value="64.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="4.3"/>
                    <measurement group_id="B2" value="22.6" spread="3.7"/>
                    <measurement group_id="B3" value="23.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pack Years Smoking History</title>
          <population>The number of subjects in the EBV and SoC group analyzed for Pack year smoking history is less than the overall population, due to missing data.</population>
          <units>pack-years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="19.6"/>
                    <measurement group_id="B2" value="42.5" spread="22.0"/>
                    <measurement group_id="B3" value="42.0" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gold stage</title>
          <description>The GOLD system uses the term &quot;stages&quot; to refer to the different levels of COPD. Participants graded as GOLD Stage III are considered to have Severe COPD. Participants graded as GOLD Stage IV are considered to have Very Severe COPD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gold Stage III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gold Stage IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Emphysema score</title>
          <description>Emphysema score was assessed as the percentage of voxels of less than -910 Hounsfield units on Computerized Tomography (CT). Scores range from 0 to 100%, with higher scores indicating more emphysematous destruction.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="7.5"/>
                    <measurement group_id="B2" value="65.8" spread="6.9"/>
                    <measurement group_id="B3" value="66.8" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heterogeneity index</title>
          <description>Difference in emphysema destruction scores between potential target and ipsilateral lung lobes, calculated from the high-resolution computer tomography scan (HRCT) read. The classification of Homogeneous or Heterogeneous emphysema follows the below criteria:
Homogeneous emphysema = heterogeneity index between target and adjacent lobes of &lt;15%.
Heterogeneous emphysema = heterogeneity index between target and adjacent lobes of ≥15%.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="5.7"/>
                    <measurement group_id="B2" value="5.0" spread="6.3"/>
                    <measurement group_id="B3" value="5.9" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (liters)</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8" spread="0.2"/>
                    <measurement group_id="B2" value="0.8" spread="0.2"/>
                    <measurement group_id="B3" value="0.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (% predicted)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="6.3"/>
                    <measurement group_id="B2" value="30.0" spread="6.6"/>
                    <measurement group_id="B3" value="29.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residual Volume (RV) (Liters)</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.1"/>
                    <measurement group_id="B2" value="5.2" spread="1.2"/>
                    <measurement group_id="B3" value="5.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residual Volume (RV) (% predicted)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277.3" spread="55.2"/>
                    <measurement group_id="B2" value="273.7" spread="63.4"/>
                    <measurement group_id="B3" value="275.4" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Lung Capacity (TLC) (Liters)</title>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.4" spread="1.6"/>
                    <measurement group_id="B2" value="7.6" spread="1.4"/>
                    <measurement group_id="B3" value="8.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Lung Capacity (TLC) (% predicted)</title>
          <units>% predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144.9" spread="21.2"/>
                    <measurement group_id="B2" value="144.2" spread="17.6"/>
                    <measurement group_id="B3" value="144.6" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC (%)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="7.2"/>
                    <measurement group_id="B2" value="35.8" spread="8.6"/>
                    <measurement group_id="B3" value="36.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RV/TLC (%)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="6.3"/>
                    <measurement group_id="B2" value="68.2" spread="7.1"/>
                    <measurement group_id="B3" value="68.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 Minute Walk Distance (meters)</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308.0" spread="91.3"/>
                    <measurement group_id="B2" value="328.3" spread="92.6"/>
                    <measurement group_id="B3" value="318.9" spread="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SGRQ Total Score</title>
          <description>The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. The questionnaire comprises of two parts:
Part I: Symptoms (frequency &amp; severity) Part II: Activities that cause or are limited by breathlessness; Impacts (social functioning, psychological disturbances resulting from airways disease)
A Total score is calculated which summarizes the impact of the disease on overall health status. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
          <population>The number of subjects in the EBV and SoC group analyzed for SGRQ Total Score is less than the overall population, due to missing data.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="13.7"/>
                    <measurement group_id="B2" value="59.3" spread="15.6"/>
                    <measurement group_id="B3" value="61.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The COPD Assessment Test (CAT) total score (derived)</title>
          <description>The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0–40 to indicate the impact of disease. Higher scores denote a more severe impact of COPD on a patient's life.</description>
          <population>The number of subjects in the SoC group analyzed for CAT Total Score, derived is less than the overall population, due to missing data.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="43"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.4" spread="6.8"/>
                    <measurement group_id="B2" value="22.8" spread="6.0"/>
                    <measurement group_id="B3" value="23.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D Summary Index</title>
          <description>EQ-5D is a standardized instrument to measure health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D health states may be converted into a single summary index by applying a formula that attaches weights to each of the levels in each dimension. The maximum score of 1 indicates the best health state, while 0 indicates the worst health state.</description>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D summary index, Europe is less than the overall population, due to missing data.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" spread="0.3"/>
                    <measurement group_id="B2" value="0.6" spread="0.2"/>
                    <measurement group_id="B3" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D health state today</title>
          <description>EQ-5D is a standardized instrument to measure health-related quality of life. The EQ-5D consists of a descriptive system and the EQ VAS (visual analogue scale). The EQ VAS corresponds to the EQ-5D health state today and records the respondent’s self-rated health on a vertical scale where the endpoints are labelled ‘Best imaginable health state’ and ‘Worst imaginable health state’. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.
Scores range from 0 to 100, with lower scores indicating worse health states.</description>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D Health State today is less than the overall population, due to missing data.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.3" spread="14.4"/>
                    <measurement group_id="B2" value="49.3" spread="19.3"/>
                    <measurement group_id="B3" value="45.2" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mMRC Dyspnea Grade score</title>
          <description>The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
          <population>The number of subjects in the EBV group analyzed for mMRC breathlessness grade is less than the overall population, due to missing data.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.8"/>
                    <measurement group_id="B2" value="2.4" spread="1.0"/>
                    <measurement group_id="B3" value="2.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BODE index</title>
          <description>The BODE Index is comprised of a person's body mass index (&quot;B&quot;), airway obstruction (&quot;O&quot;), dyspnea (&quot;D&quot;), and exercise tolerance (&quot;E&quot;). Each of these components is graded on a scale of either 0 to 1 or 0 to 3. The final value—ranging from 0 to 10—provides doctors a percentage of how likely a person is to survive for four years. The final BODE tabulation is described as follows:
0 to 2 points: 80 percent likelihood of survival 3 to 4 points: 67 percent likelihood of survival 5 of 6 points: 57 percent likelihood of survival 7 to 10 points: 18 percent likelihood of survival</description>
          <population>The number of subjects in the EBV group analyzed for BODE index is less than the overall population, due to missing data.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="42"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.4"/>
                    <measurement group_id="B2" value="5.2" spread="1.7"/>
                    <measurement group_id="B3" value="5.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D Mobility</title>
          <population>The number of subjects in the EBV and SOC group analyzed for EQ-5D mobility is less than the overall population, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Confined to bed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D Self-Care</title>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D Self-Care is less than the overall population, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D usual activities</title>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D Usual Activities is less than the overall population, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D Pain/Discomfort</title>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D pain/discomfort is less than the overall population, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EQ-5D Anxiety/Depression</title>
          <population>The number of subjects in the EBV and SoC group analyzed for EQ-5D anxiety/depression is less than the overall population, due to missing data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="41"/>
                    <count group_id="B2" value="48"/>
                    <count group_id="B3" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Forced Expiratory Volume in 1 s (FEV1) (ITT Population)</title>
        <description>Percentage change in FEV1 at 3 months relative to Baseline in the EBV group, compared to the SoC group.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Forced Expiratory Volume in 1 s (FEV1) (ITT Population)</title>
          <description>Percentage change in FEV1 at 3 months relative to Baseline in the EBV group, compared to the SoC group.</description>
          <population>ITT population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="28.2"/>
                    <measurement group_id="O2" value="-3.2" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Target Lobe Volume for EBV Group (ITT Population)</title>
        <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Target Lobe Volume for EBV Group (ITT Population)</title>
          <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1195" spread="683.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Target Lobe Volume for EBV Group (ITT Population)</title>
        <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Target Lobe Volume for EBV Group (ITT Population)</title>
          <description>Target Lobe Volume Reduction (TLVR) was evaluated by quantitative analysis of HRCT scans at Baseline and at 3-months post-valve placement to measure the target lobe volume.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects in the EBV Group With a Target Lobe Volume Reduction (TLVR) of ≥ 350ml at 3 Months</title>
        <description>The threshold of TLVR ≥350 mL was used to determine the proportion of subjects that achieved this amount of TLVR in the EBV group.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects in the EBV Group With a Target Lobe Volume Reduction (TLVR) of ≥ 350ml at 3 Months</title>
          <description>The threshold of TLVR ≥350 mL was used to determine the proportion of subjects that achieved this amount of TLVR in the EBV group.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in FEV1 (L) Post Bronchodilator at 3 Months</title>
        <description>The mean absolute change in FEV1(L) relative to Baseline at 3 months between the EBV and SoC groups</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in FEV1 (L) Post Bronchodilator at 3 Months</title>
          <description>The mean absolute change in FEV1(L) relative to Baseline at 3 months between the EBV and SoC groups</description>
          <population>ITT population</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="-0.02" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in FEV1 (% Predicted) Post Bronchodilator at 3 Months</title>
        <description>The mean absolute change in FEV1(% Predicted) relative to Baseline at 3 months between the EBV and SoC groups</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in FEV1 (% Predicted) Post Bronchodilator at 3 Months</title>
          <description>The mean absolute change in FEV1(% Predicted) relative to Baseline at 3 months between the EBV and SoC groups</description>
          <population>ITT population</population>
          <units>Percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="6.5"/>
                    <measurement group_id="O2" value="-1.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Residual Volume (RV) at 3 Months</title>
        <description>Mean absolute change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Residual Volume (RV) at 3 Months</title>
          <description>Mean absolute change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
          <population>ITT population</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.9"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Residual Volume (RV) at 3 Months</title>
        <description>Mean percent change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Residual Volume (RV) at 3 Months</title>
          <description>Mean percent change in Residual Volume relative to Baseline at 3 months between the EBV and SoC groups</description>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="13.6"/>
                    <measurement group_id="O2" value="2.7" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Predicted Change in Residual Volume at 3 Months</title>
        <description>Percent predicted change in RV relative to Baseline at 3 months between the EBV and SoC groups</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Predicted Change in Residual Volume at 3 Months</title>
          <description>Percent predicted change in RV relative to Baseline at 3 months between the EBV and SoC groups</description>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.1" spread="47.6"/>
                    <measurement group_id="O2" value="-0.3" spread="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Six-Minute Walk Distance at 3 Months</title>
        <description>Mean absolute change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Six-Minute Walk Distance at 3 Months</title>
          <description>Mean absolute change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
          <population>ITT population</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="66.6"/>
                    <measurement group_id="O2" value="-17.3" spread="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Six-Minute Walk Distance at 3 Months</title>
        <description>Mean percent change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Six-Minute Walk Distance at 3 Months</title>
          <description>Mean percent change in the 6MWD from Baseline to 3 months in the EBV group compared to the SOC</description>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="26.5"/>
                    <measurement group_id="O2" value="-3.9" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the SGRQ Total Score From Baseline to 3 Months</title>
        <description>Mean absolute change in the St. George's Respiratory Questionnaire Total Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the SGRQ Total Score From Baseline to 3 Months</title>
          <description>Mean absolute change in the St. George's Respiratory Questionnaire Total Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
          <population>ITT population</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="11.3"/>
                    <measurement group_id="O2" value="1.0" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change (%) in the SGRQ Total Score From Baseline to 3 Months</title>
        <description>Mean percent change in the SGRQ Total Score from Baseline to 3 months in the EBV group compared to the SoC group</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change (%) in the SGRQ Total Score From Baseline to 3 Months</title>
          <description>Mean percent change in the SGRQ Total Score from Baseline to 3 months in the EBV group compared to the SoC group</description>
          <population>ITT population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="19.5"/>
                    <measurement group_id="O2" value="3.9" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the mMRC Dyspnea Score From Baseline to 3 Months</title>
        <description>Mean absolute change in the Modified Medical Research Council (mMRC) Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the mMRC Dyspnea Score From Baseline to 3 Months</title>
          <description>Mean absolute change in the Modified Medical Research Council (mMRC) Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
          <population>ITT population</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.0"/>
                    <measurement group_id="O2" value="0.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change (%) in the mMRC Dyspnea Score From Baseline to 3 Months</title>
        <description>Mean percent change in the mMRC Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change (%) in the mMRC Dyspnea Score From Baseline to 3 Months</title>
          <description>Mean percent change in the mMRC Dyspnea Score from Baseline to 3 months in the EBV group compared to the SoC group. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.</description>
          <population>ITT population</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="40.0"/>
                    <measurement group_id="O2" value="14.3" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in the CAT Total Score From Baseline to 3 Months</title>
        <description>Mean absolute change in the COPD Assessment Test (CAT) Total Score from Baseline to 3 months in the EBV group compared to the SoC group.
The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in the CAT Total Score From Baseline to 3 Months</title>
          <description>Mean absolute change in the COPD Assessment Test (CAT) Total Score from Baseline to 3 months in the EBV group compared to the SoC group.
The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease.</description>
          <population>ITT population</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="5.6"/>
                    <measurement group_id="O2" value="-0.7" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change (%) in CAT Total Score From Baseline to 3 Months</title>
        <description>The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease. Higher scores denote a more severe impact of COPD on a patient's life.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change (%) in CAT Total Score From Baseline to 3 Months</title>
          <description>The COPD Assessment Test (CAT) is an eight-item questionnaire designed to quantify the impact of COPD symptoms on the health status of patients. The CAT provides a score of 0-40 to indicate the impact of disease. Higher scores denote a more severe impact of COPD on a patient's life.</description>
          <population>ITT population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="30.2"/>
                    <measurement group_id="O2" value="-0.9" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in EQ-5D Summary Index From Baseline to 3 Months</title>
        <description>Mean absolute change in the EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.
EQ-5D is a standardized instrument to measure health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D health states may be converted into a single summary index by applying a formula that attaches weights to each of the levels in each dimension. The maximum score of 1 indicates the best health state, while 0 indicates the worst health state.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in EQ-5D Summary Index From Baseline to 3 Months</title>
          <description>Mean absolute change in the EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.
EQ-5D is a standardized instrument to measure health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS.
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D health states may be converted into a single summary index by applying a formula that attaches weights to each of the levels in each dimension. The maximum score of 1 indicates the best health state, while 0 indicates the worst health state.</description>
          <population>ITT population</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.01" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change (%) in EQ-5D Summary Index From Baseline to 3 Months</title>
        <description>Mean percent change in EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change (%) in EQ-5D Summary Index From Baseline to 3 Months</title>
          <description>Mean percent change in EQ-5D Summary Index from Baseline to 3 months in the EBV group compared to the SoC group.</description>
          <population>ITT population</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7" spread="70.1"/>
                    <measurement group_id="O2" value="26.2" spread="115.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in EQ-5D VAS (Health State Today) Score From Baseline to 3 Months</title>
        <description>Mean absolute change in the EQ-5D VAS (Health State Today) Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating better outcome.</description>
        <time_frame>At baseline and after 3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>BLVR With Zephyr Endobronchial Valves</title>
            <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in EQ-5D VAS (Health State Today) Score From Baseline to 3 Months</title>
          <description>Mean absolute change in the EQ-5D VAS (Health State Today) Score from Baseline to 3 months in the EBV group compared to the SoC group. Scores range from 0 to 100, with higher scores indicating better outcome.</description>
          <population>ITT population</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="17.7"/>
                    <measurement group_id="O2" value="-0.4" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BLVR With Zephyr Endobronchial Valves</title>
          <description>Bronchoscopic Lung Volume Reduction with Zephyr Endobronchial Valves
Endobronchial Valve: Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr Endobronchial Valve</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diagnostic bronchoscopy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucus production</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary granulations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary shunt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thoracic pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pulmonary lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Narinder Shargill, Vice President, Global Medical and Clinical Affairs</name_or_title>
      <organization>Pulmonx</organization>
      <phone>650-216-0108</phone>
      <email>nshargill@pulmonx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

